These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8745694)

  • 1. [Macrophage activation syndrome. Cutaneous manifestations].
    Béraud V; Kone-Paut I; Sebahoun G; Berbis P
    Ann Dermatol Venereol; 1995; 122(9):632-6. PubMed ID: 8745694
    [No Abstract]   [Full Text] [Related]  

  • 2. Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood.
    Avcin T; Tse SM; Schneider R; Ngan B; Silverman ED
    J Pediatr; 2006 May; 148(5):683-6. PubMed ID: 16737887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous manifestations of the rheumatic diseases.
    Gilkes JJ
    Practitioner; 1978 Jan; 220(1315):68-72. PubMed ID: 305042
    [No Abstract]   [Full Text] [Related]  

  • 4. [Macrophage activation syndrome in lupus].
    Javier RM; Sibilia J; Offner C; Albert A; Kuntz JL
    Rev Rhum Ed Fr; 1993 Nov; 60(11):831-5. PubMed ID: 8054932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lupus erythematosus: systemic and cutaneous manifestations.
    Rothfield N; Sontheimer RD; Bernstein M
    Clin Dermatol; 2006; 24(5):348-62. PubMed ID: 16966017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of macrophage activation syndrome developed with systemic juvenile rheumatoid arthritis].
    Imagawa T; Katakura S; Mori M; Aihara Y; Mitsuda T; Yokota S
    Ryumachi; 1997 Jun; 37(3):487-92. PubMed ID: 9256033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Disseminated lupus erythematosus. Antiphospholipid syndrome. Cutaneous-mucous manifestations of systemic lupus erythematosus].
    Francés C; Crickx B; Beylot C
    Ann Dermatol Venereol; 2002 Oct; 129(10 Suppl):S102-5. PubMed ID: 12718134
    [No Abstract]   [Full Text] [Related]  

  • 8. Recognition and management of macrophage activation syndrome in juvenile arthritis.
    Kelly A; Ramanan AV
    Curr Opin Rheumatol; 2007 Sep; 19(5):477-81. PubMed ID: 17762614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis.
    Behrens EM; Beukelman T; Paessler M; Cron RQ
    J Rheumatol; 2007 May; 34(5):1133-8. PubMed ID: 17343315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept in the treatment of macrophage activation syndrome.
    Prahalad S; Bove KE; Dickens D; Lovell DJ; Grom AA
    J Rheumatol; 2001 Sep; 28(9):2120-4. PubMed ID: 11550985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage activation syndrome in juvenile systemic lupus erythematosus: an under-recognized complication?
    Pringe A; Trail L; Ruperto N; Buoncompagni A; Loy A; Breda L; Martini A; Ravelli A
    Lupus; 2007; 16(8):587-92. PubMed ID: 17711893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case report of macrophage activation syndrome complicated by systemic onset juvenile idiopathic arthritis].
    Zhao Y; Cao LF
    Zhongguo Dang Dai Er Ke Za Zhi; 2007 Dec; 9(6):610. PubMed ID: 18082055
    [No Abstract]   [Full Text] [Related]  

  • 13. Macrophage activation syndrome and etanercept in children with systemic juvenile rheumatoid arthritis.
    Sawar H; Espinoza LR; Gedalia A
    J Rheumatol; 2004 Mar; 31(3):623; author reply 623-4. PubMed ID: 14994420
    [No Abstract]   [Full Text] [Related]  

  • 14. The clinical spectrum and treatment options of macrophage activation syndrome in the pediatric age.
    Stabile A; Bertoni B; Ansuini V; La Torraca I; Sallì A; Rigante D
    Eur Rev Med Pharmacol Sci; 2006; 10(2):53-9. PubMed ID: 16705949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis.
    Bleesing J; Prada A; Siegel DM; Villanueva J; Olson J; Ilowite NT; Brunner HI; Griffin T; Graham TB; Sherry DD; Passo MH; Ramanan AV; Filipovich A; Grom AA
    Arthritis Rheum; 2007 Mar; 56(3):965-71. PubMed ID: 17328073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome.
    Maeno N; Takei S; Imanaka H; Yamamoto K; Kuriwaki K; Kawano Y; Oda H
    Arthritis Rheum; 2004 Jun; 50(6):1935-8. PubMed ID: 15188370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophage activation syndrome: a frequent but under-diagnosed complication associated with rheumatic diseases.
    Tristano AG
    Med Sci Monit; 2008 Mar; 14(3):RA27-36. PubMed ID: 18301366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable outcome in patients with renal involvement complicating macrophage activation syndrome in systemic onset juvenile rheumatoid arthritis.
    Ramanan AV; Rosenblum ND; Feldman BM; Laxer RM; Schneider R
    J Rheumatol; 2004 Oct; 31(10):2068-70. PubMed ID: 15468377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic lupus erythematosus with major organ involvement in a patient with systemic-onset juvenile idiopathic arthritis.
    Sarma PK; Agrawal S; Aggarwal A; Misra R
    J Rheumatol; 2007 Apr; 34(4):893-4. PubMed ID: 17407252
    [No Abstract]   [Full Text] [Related]  

  • 20. [Cutaneous manifestations of lupus in children].
    Bodemer C
    Arch Pediatr; 2004 Jun; 11(6):509-11. PubMed ID: 15158813
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.